HK1201685A1 - Pazopanib formulation - Google Patents

Pazopanib formulation Download PDF

Info

Publication number
HK1201685A1
HK1201685A1 HK15102188.1A HK15102188A HK1201685A1 HK 1201685 A1 HK1201685 A1 HK 1201685A1 HK 15102188 A HK15102188 A HK 15102188A HK 1201685 A1 HK1201685 A1 HK 1201685A1
Authority
HK
Hong Kong
Prior art keywords
formulation
pazopanib
pazopanib formulation
methylbenzenesulfonamide
indazol
Prior art date
Application number
HK15102188.1A
Other languages
English (en)
Chinese (zh)
Inventor
Campbell Gossets Augustus
Helen RICHARDSON
Peter A. WILLIAMS
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1201685A1 publication Critical patent/HK1201685A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15102188.1A 2011-10-31 2012-10-16 Pazopanib formulation HK1201685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553454P 2011-10-31 2011-10-31
US61/553,454 2011-10-31
PCT/US2012/060361 WO2013066616A1 (en) 2011-10-31 2012-10-16 Pazopanib formulation

Publications (1)

Publication Number Publication Date
HK1201685A1 true HK1201685A1 (en) 2015-09-11

Family

ID=48192602

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102188.1A HK1201685A1 (en) 2011-10-31 2012-10-16 Pazopanib formulation

Country Status (12)

Country Link
US (3) US9278099B2 (enExample)
EP (1) EP2773204A4 (enExample)
JP (2) JP6200893B2 (enExample)
KR (1) KR101993436B1 (enExample)
CN (1) CN104254249B (enExample)
AU (1) AU2012332952B2 (enExample)
BR (1) BR112014010551A2 (enExample)
CA (1) CA2852912A1 (enExample)
HK (1) HK1201685A1 (enExample)
IN (1) IN2014CN02850A (enExample)
RU (1) RU2616500C2 (enExample)
WO (1) WO2013066616A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA201502073B (en) * 2014-03-28 2016-03-30 Cipla Ltd Pharmaceutical composition
CN110753546B (zh) * 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
WO2019053500A1 (en) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
IL278161B2 (en) 2018-04-24 2024-12-01 Shionogi & Co Solid dosage form with excellent stability
AU2019259686B2 (en) 2018-04-24 2023-05-25 Shionogi & Co., Ltd. Solid formulation having excellent stability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675537A5 (enExample) 1988-03-25 1990-10-15 Ciba Geigy Ag
DE58903964D1 (de) * 1988-11-10 1993-05-06 Ciba Geigy Ag Fluessige orale formulierung.
EP1343782B1 (en) * 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
HRP20020923A2 (en) * 2001-11-23 2003-10-31 Glaxo Group Ltd Pharmaceutical composition
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
US20080293691A1 (en) * 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
ATE500831T1 (de) * 2005-11-29 2011-03-15 Glaxosmithkline Llc Krebsbehandlungsverfahren
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
WO2010037095A2 (en) * 2008-09-29 2010-04-01 Nometics Agents and methods for the treatment of cancer
US20100291025A1 (en) 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses

Also Published As

Publication number Publication date
US20160120988A1 (en) 2016-05-05
EP2773204A4 (en) 2015-05-27
KR101993436B1 (ko) 2019-06-26
CN104254249A (zh) 2014-12-31
US9278099B2 (en) 2016-03-08
CN104254249B (zh) 2017-02-15
BR112014010551A2 (pt) 2017-05-02
JP2017197542A (ja) 2017-11-02
AU2012332952B2 (en) 2016-05-05
CA2852912A1 (en) 2013-05-10
RU2014115289A (ru) 2015-12-10
US20140255505A1 (en) 2014-09-11
US20180360971A1 (en) 2018-12-20
JP2014534215A (ja) 2014-12-18
US10596263B2 (en) 2020-03-24
JP6423484B2 (ja) 2018-11-14
US10080802B2 (en) 2018-09-25
IN2014CN02850A (enExample) 2015-07-03
JP6200893B2 (ja) 2017-09-20
AU2012332952A1 (en) 2014-05-15
RU2616500C2 (ru) 2017-04-17
KR20140096082A (ko) 2014-08-04
WO2013066616A1 (en) 2013-05-10
EP2773204A1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
UA103332C2 (ru) Фармацевтическая композиция, которая содержит непептидный активный агент с первичной или вторичной аминогруппой
MX2010004576A (es) Derivados de pirimidina novedosos.
HK1201685A1 (en) Pazopanib formulation
IL221086A0 (en) 4-[cycloalkyloxy (hetero) arylamino] thieno [2,3-d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
EP3068394A4 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2009084021A3 (en) Ophthalmic composition comprising a prostaglandin
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2014096985A3 (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
EP4424375A3 (en) Antineoplastic combinations of neratinib and capecitabine
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
NZ598427A (en) Stabilized amorphous forms of imatinib mesylate with cyclodextrin complex
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
WO2012046009A8 (en) Composition for intraocular implantation of bevacizumab
WO2011079193A3 (en) Preparation of bendamustine and its salts
PH12012501340A1 (en) Composition for improving brain function and method for improving brain function
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2014145314A3 (en) Methods and compositions for gamma-glutamyl cycle modulation
WO2009016069A3 (en) Stable liquid pharmaceutical composition based on trazodone
WO2010012940A3 (fr) Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2012056294A8 (en) An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-l-valine